美国 · SEC FORM 4
Salarius Pharmaceuticals, Inc.
SLRX · Nasdaq · CIK 0001615219 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
10 同一窗口内观察到的 Form 4 交易行
0 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-11-20 · HANISH ARNOLD C.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-11-20 | HANISH ARNOLD C | 买入 (P) | Common Stock | 5,000 | USD 0.75 | USD 3,750 | SEC 申报 ↗ |
| 2025-11-20 | Rosenblum Mark J | 买入 (P) | Common Stock | 20,000 | USD 0.80 | USD 16,000 | SEC 申报 ↗ |
| 2022-06-07 | Lieber Jonathan I | 买入 (P) | Common Stock | 37,500 | USD 0.19 | USD 7,125 | SEC 申报 ↗ |
| 2022-06-07 | Burleson Tess | 买入 (P) | Common Stock | 27,700 | USD 0.18 | USD 4,986 | SEC 申报 ↗ |
| 2022-06-06 | McVicar William K. | 买入 (P) | Common Stock | 26,553 | USD 0.19 | USD 5,045 | SEC 申报 ↗ |
| 2022-06-03 | HANISH ARNOLD C | 买入 (P) | Common Stock | 28,000 | USD 0.18 | USD 5,040 | SEC 申报 ↗ |
| 2022-05-31 | Rosenblum Mark J | 买入 (P) | Common Stock | 28,000 | USD 0.18 | USD 5,040 | SEC 申报 ↗ |
| 2022-05-26 | Arthur David J. | 买入 (P) | Common Stock | 43,900 | USD 0.18 | USD 7,902 | SEC 申报 ↗ |
| 2022-03-03 | Rosenblum Mark J | 买入 (P) | Common Stock | 76,246 | USD 0.39 | USD 29,736 | SEC 申报 ↗ |
| 2022-03-03 | Arthur David J. | 买入 (P) | Common Stock | 139,488 | USD 0.39 | USD 54,400 | SEC 申报 ↗ |
| 2021-08-17 | Arthur David J. | 买入 (P) | Common Stock | 4,000 | USD 0.90 | USD 3,580 | SEC 申报 ↗ |
| 2021-08-10 | HANISH ARNOLD C | 买入 (P) | Common Stock | 7,000 | USD 0.88 | USD 6,160 | SEC 申报 ↗ |
| 2020-08-21 | HANISH ARNOLD C | 买入 (P) | Common Stock | 4,000 | USD 0.98 | USD 3,920 | SEC 申报 ↗ |
| 2020-08-21 | HANISH ARNOLD C | 买入 (P) | Common Stock | 4,000 | USD 0.98 | USD 3,920 | SEC 申报 ↗ |
| 2020-08-19 | Arthur David J. | 买入 (P) | Common Stock | 1,000 | USD 1.01 | USD 1,010 | SEC 申报 ↗ |
Form 4 申报证据
14 transaction lines in the latest 365-day window; 67 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Rosenblum Mark J | 奖励／授予 (A) | Common Stock | 9,682 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | PIERCE FREDERICK II | 奖励／授予 (A) | Common Stock | 33,455 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | McVicar William K. | 奖励／授予 (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (13 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Rosenblum Mark J | 奖励／授予 (A) | Common Stock | 9,682 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | PIERCE FREDERICK II | 奖励／授予 (A) | Common Stock | 33,455 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | McVicar William K. | 奖励／授予 (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Marschel Peter Klaus | 奖励／授予 (A) | Common Stock | 3,900 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Lieber Jonathan I | 奖励／授予 (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Lammers Paul | 奖励／授予 (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Hibner Barbara Louise | 奖励／授予 (A) | Common Stock | 4,216 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | HANISH ARNOLD C | 奖励／授予 (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Gauthier Patricia G. | 奖励／授予 (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-31 | Burleson Tess | 奖励／授予 (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-30 | HANISH ARNOLD C | 卖出 (S) | Common Stock | 27 | USD 0.64 | USD 17 | SEC 申报 ↗ |
| 2025-11-20 | HANISH ARNOLD C | 买入 (P) | Common Stock | 5,000 | USD 0.75 | USD 3,750 | SEC 申报 ↗ |
| 2025-11-20 | Rosenblum Mark J | 买入 (P) | Common Stock | 20,000 | USD 0.80 | USD 16,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SLRX |
| CIK | 0001615219 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 67 transaction lines from 2020-02-11 to 2026-08-31 31 P purchase lines · 2 S sale lines · 34 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.